Merck & Co and Sun Pharmaceutical are winding down their 2011 joint venture focused on developing branded generics for emerging markets outside of India.
Sun Pharma said the move follows a change of strategic priorities for both partners, which have decided not to invest further in the JV.
Dilip Shanghvi, Sun’s managing director, reportedly told analysts that the firm’s investment in the venture is not significant and has been factored into the company’s financials over time, according to The Hindu Business Line.
Other agreements between the firms – the co-marketing deal for Merck’s diabetes drug Januvia (sitagliptin) and licensing deal for Merck’s investigational psoriasis therapy tildrakizumab – remain unaffected by the decision, the Indian generics giant stressed.
By Selina McKee
Source: Pharma Times
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.
